Wednesday, September 23, 2020 The results for the CCTG PA7 trial were recently presented at the European Society for Medical Oncology (ESMO) virtual Congress. The CCTG lead for this study, Dr. Daniel Renouf, reported on key results of the PA7 Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line study. Dr Renouf concluded that, “This trial demonstrated that the use of the combination treatment did not result in increased efficacy.” Please see the video below for the overview of the trial results presented at ESMO. CCTG Senior Investigator, Chis O'Callaghan says that, "Although the PA7 trial did not demonstrate an overall benefit for patients receiving durvalumab and tremelimumab in addition to standard of care chemotherapy, correlative analyses are underway to determine whether a subgroup deriving benefit can be identified. Results of those analyses are expected to be presented at the 2021 GI ASCO Symposium." For information about the trial please see the CCTG PA7 trial page.
